Showing 1 - 10 of 62 Cancers and Other Neoplasms

Status: Enrolling

Investigator: Warren Ellsworth

Study Coordinator:

Phone:

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator:

Phone:

Breast implants are the most common way of rebuilding the shape of the breasts after breast cancer surgery. However, current breast implants cannot completely match individual differences in breast shape. It is also often difficult to match the ... Read more >

Status: Active

Investigator: Eric Bernicker

Study Coordinator: Daniel (cancer) Le (cancer)

Phone: 346.238.5655

Keynote 695 will be a Phase 2 study of intratumoral tavokinogene telseplasmid (tavo; pIL-12) Electroporation (EP) plus IV Pembrolizumab. Eligible patients will be those with pathological diagnosis of unresectable or metastatic melanoma who are p ... Read more >

Status: Enrolling

Investigator: Aldona Spiegel

Study Coordinator:

Phone:

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >

Status: Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them una ... Read more >

Status: Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got worse) after stoppi ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Steven Hepp

Phone: 802.793.3352

To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab. ... Read more >

Status: Enrolling

Investigator: Aparna Kamat

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

The study evaluates the response to treatment with Ribociclib and Letrozole in patients with recurrent low grade serous cancer of the ovary, fallopian tube or peritoneum. ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Steven Hepp

Phone: 802.793.3352

This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutation ... Read more >

Status: Open Not Enrolling

Investigator: Raj Satkunasivam

Study Coordinator: Cinthya Yesenia Obando Perez

Phone: 346.238.6123

This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder ... Read more >

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator:

Phone:

This is a pilot study is evaluating the effect of hydroxytyrosol, a component of Olive oil, on mammographic density in women at high risk of breast through assessing whether mammographic density is reduced in women at high risk of breast cancer ... Read more >

Status: Enrolling

Investigator: Sandra Templeton

Study Coordinator: Erick Villarreal-Williams

Phone: 346.238.5594

This is a prospective cohort study for patients diagnosed with ductal carcinoma in situ (DCIS) of the breast. The primary objective of the study is to create a de-identified database of patients, test results, treatment decisions and outcomes th ... Read more >

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Daniel (cancer) Le (cancer)

Phone: 346.238.5655

This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet know ... Read more >

Status: Enrolling

Investigator: Tarrik Zaid

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

This randomized phase III trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy and cisplatin alone in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA c ... Read more >

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator:

Phone:

The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. (A placebo is a dru ... Read more >

Status: Enrolling

Investigator: Dharamvir Jain

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic). Drugs used in chemothera ... Read more >

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Larisse Yewah Gwei

Phone: 713.441.3834

This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) follow ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

Major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR rate of pembrolizumab as a single agent. Additionally the dynami ... Read more >

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Mary Rose Silvas

Phone: 713.441.1952

This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. ... Read more >

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first-line treatment) as measured by Progression Free Survival (PFS). This study will also ev ... Read more >

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Raquel Araujo

Phone: 713.363.9363

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Daniel (cancer) Le (cancer)

Phone: 346.238.5655

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment ... Read more >

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator:

Phone:

A single arm pilot study of 20 patients will be used to determine the feasibility of EA as a treatment for cancer survivors who have been treated with curative intent, but who have persistent CIPN for ?3 months after the cancer treatment is comp ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in diffe ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Mary Rose Silvas

Phone: 713.441.1952

This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving surgery. Tumor tissue collected from biopsy before surgery ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Toniva Boone

Phone: 713.441.0686

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. ... Read more >

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Caroline Fitzgerald

Phone: 713.441.3250

This is a study to determine the maximum tolerated dose (MTD) for CDX-1140, either alone or in combination with CDX-301, and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined. ... Read more >

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This is a Phase Ib/II study assessing the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), recommended Phase 2 dose (RP2D), and efficacy of L-NMMA when combined with docetaxel in refractory locally advanced or metastatic triple neg ... Read more >

Status: Enrolling

Investigator: Aparna Kamat

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

The purpose of this study is to prospectively collect de-identified biological samples and data from women with a known pelvic mass, in order to validate ovarian cancer specific glycoproteomic signatures in the blood based on histologically conf ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator:

Phone:

Hormone receptor positive breast cancer HRBC is the most common cause of BC-related death. HRBC is characterized by a non-immunogenic microenvironment and consequently, modest responses have been observed with immune checkpoint blockade ICB alon ... Read more >

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Mary Rose Silvas

Phone: 713.441.1952

The purpose of this exploratory biomarker study is to further our understanding of the role of cancer stem cells (CSCs) and other biomarkers in the progression of COPD to lung cancer by examining the CSC population and other related biomarkers, ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5268

The reason for this trial is to compare DS-8201a to other treatments being used for HER2-low breast cancer that has spread to other parts of the body. DS-8201a is a new medicine for breast cancer that has not been approved yet by the Food and ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Erick Villarreal-Williams

Phone: 346.238.5594

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane. ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator:

Phone:

Primary Objective: • To compare the efficacy of DS-8201a to investigator’s choice by means of progression-free survival (PFS). Secondary Objectives: • To further investigate the efficacy of DS-8201a compared to investigator’s choice on: ? ... Read more >

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5268

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3 ... Read more >

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5268

The purpose of this exploratory biomarker study is to further our understanding of the role of CSCs in lung cancer metastasis by examining the CSC population in metastatic tissue. ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This is a Phase I/Ib study testing the safety and preliminary efficacy of olaparib and vorinostat when used together in participants with relapsed/refractory and or metastatic breast cancer. Cancer cells grow in an uncontrolled manner and this c ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer. ... Read more >

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

The study is an open-label, randomized, phase III trial to evaluate the addition of atezolizumab to standard chemoradiation for limited stage small cell lung cancer. Patients will be enrolled and randomized 1:1 between chemoradiation + atezolizu ... Read more >

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Helga Jones

Phone: 713.363.9388

" Purpose The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site p ... Read more >

Status: Open Not Enrolling

Investigator: Charles Geyer

Study Coordinator:

Phone:

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). ... Read more >

Status: Enrolling

Investigator: Aparna Kamat

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). Drug ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator:

Phone:

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand t ... Read more >

Status: Enrolling

Investigator: Raj Satkunasivam

Study Coordinator:

Phone:

This is a Phase 3, Multicenter, Double-blind, Randomized, Placebo-Controlled Trial to evaluate the efficacy of Infigratinib in adult patients with invasive urothelial carcinoma with susceptible FGFR3 genetic alterations (mutations, and gene fusi ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Jose Cruz

Phone: 713.441.4457

This is an open-label, randomized, multicenter Phase 3 study to compare the efficacy and safety of Sacituzumab Govitecan versus TPC in subjects with metastatic or locally recurrent inoperable HR+/HER2- MBC, after failure of at least 2, and no mo ... Read more >

Status: Enrolling

Investigator: Jorge Darcourt

Study Coordinator: Daniel (cancer) Le (cancer)

Phone: 346.238.5655

The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), ... Read more >

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Britney Buchanan

Phone: 713.441.5607

This is a phase Ib/II Study of Leronlimab (PRO 140) combined with Carboplatin in Patients with CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC). Study population will consist of patients with CCR5-positive, locally advanced or metastati ... Read more >

Status: Enrolling

Investigator: Jorge Darcourt

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5268

This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy. At least 140 patients are anticipated to be enrolle ... Read more >

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator:

Phone:

The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast cancer who have failed anthracycline based therap ... Read more >

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Britney Buchanan

Phone: 713.441.5607

This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment before pembrolizumab in patients with metastatic triple neg ... Read more >

Status: Enrolling

Investigator: Aparna Kamat

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kil ... Read more >

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Larisse Yewah Gwei

Phone: 713.441.3834

NCT03603405 This is a prospective, phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy for anaplastic astrocytoma (AA) or glioblastoma mul ... Read more >

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Larisse Yewah Gwei

Phone: 713.441.3834

NCT03596086 This is a prospective phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy in recurrent anaplastic astrocytoma or glioblastoma ... Read more >

Status: Enrolling

Investigator: Jorge Darcourt

Study Coordinator:

Phone:

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

The purpose of this pilot study is to characterize the composition/diversity of the gut microbiome in patients with metastatic NSCLC who are receiving standard of care checkpoint blockade immunotherapy. This study will lay the groundwork for lar ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop t ... Read more >

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Latasha Senegal

Phone: 713.441.1159

This study is investigating whether breast cancer patients who experience vaginal dryness while on anti-estrogen treatment could benefit from either vaginal estrogen or from a vaginal moisturizer called Replens. ... Read more >

Status: Enrolling

Investigator: Kirk Heyne

Study Coordinator: Caroline Fitzgerald

Phone: 713.441.3250

The purpose of this study is to investigate nivolumab combined with Debio 1143. The study will focus on subjects with specific solid tumors for whom tumors were previously treated with anti-PD-1/PD-L1 therapy as a single therapy (or when used wi ... Read more >

Status: Enrolling

Investigator: Kirk Heyne

Study Coordinator:

Phone:

This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced uro ... Read more >

Status: Enrolling

Investigator: Raj Satkunasivam

Study Coordinator: Cinthya Yesenia Obando Perez

Phone: 346.238.6123

Primary Purpose: Treatment ... Read more >

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator:

Phone:

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exem ... Read more >

Status: Enrolling

Investigator: Mark Sultenfuss

Study Coordinator:

Phone:

This research registry studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting Selective Internal Radiation-Spheres (SIR-spheres ... Read more >